Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook

Merck announced a multi-year optimization initiative to slash $3 billion in costs by 2027, which will be fully reinvested into its pipeline and new product launches to offset the 2028 Keytruda patent expiration and prepare for potential tariffs. This strategic move follows a Q2 revenue miss, the first since April 2021, primarily due to a 55% sales decline for Gardasil driven by persistent demand issues in China, leading to shipment halts through at least end-2025. Despite these challenges, Keytruda sales grew 9%, and the new drug Winrevair outperformed expectations, while the company also narrowed its full-year 2025 guidance.

Analysis

Merck is undertaking a significant strategic pivot, initiating a $3 billion cost optimization program to be completed by 2027. This proactive restructuring is designed to fund its pipeline and new product launches, directly addressing the material revenue threat from the 2028 patent expiration of its blockbuster drug, Keytruda. The urgency of this shift is highlighted by the company's second-quarter results, which featured its first revenue miss since April 2021, with revenue of $15.81 billion falling short of the $15.89 billion consensus. The primary driver of this underperformance was a severe 55% year-over-year decline in Gardasil sales, stemming from a halt in shipments to China due to soft demand and high inventory, a situation now expected to persist through at least the end of 2025. Despite these headwinds, Keytruda sales grew 9% to $7.96 billion, slightly beating expectations, and the new drug Winrevair delivered a strong launch with $336 million in sales. The company narrowed its full-year guidance, slightly raising the low end of its EPS forecast, but this outlook excludes the impact of its recent Verona Pharma acquisition and potential future pharmaceutical-specific tariffs, leaving some uncertainty.

Key Decisions for Investors

• Investors should focus on the execution of the multi-year restructuring plan and the sales ramp-up of new products like Winrevair, as these are the primary drivers intended to offset the looming Keytruda patent cliff.
• The prolonged disruption to Gardasil sales in China, now expected to last through 2025, represents a significant near-to-medium term revenue headwind that needs to be factored into valuation models.
• While the narrowed guidance provides some stability, consider the unquantified risks from potential future tariffs and the financial integration of the Verona Pharma acquisition, as these are not yet reflected in the company's outlook.
• Given the mixed signals of a major product's decline against pipeline successes and continued Keytruda growth, a neutral to cautiously optimistic stance may be warranted, pending further clarity on the Gardasil recovery and restructuring milestones.